[go: up one dir, main page]

MX2008010801A - Indolopiridinas como moduladores de quinesina eg5. - Google Patents

Indolopiridinas como moduladores de quinesina eg5.

Info

Publication number
MX2008010801A
MX2008010801A MX2008010801A MX2008010801A MX2008010801A MX 2008010801 A MX2008010801 A MX 2008010801A MX 2008010801 A MX2008010801 A MX 2008010801A MX 2008010801 A MX2008010801 A MX 2008010801A MX 2008010801 A MX2008010801 A MX 2008010801A
Authority
MX
Mexico
Prior art keywords
indolopyridines
kinesin modulators
kinesin
modulators
compounds
Prior art date
Application number
MX2008010801A
Other languages
English (en)
Inventor
Matthias Vennemann
Thomas Baer
Juergen Braunger
Astrid Zimmermann
Volker Gekeler
Original Assignee
4Sc Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Ag filed Critical 4Sc Ag
Publication of MX2008010801A publication Critical patent/MX2008010801A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de una cierta fórmula (I), en donde R1, R2, R3, R4, R5 y R6 tienen los significados indicados en la descripción, son compuestos eficaces con actividad antiproliferativa y/o inductora de apoptosis. (ver fórmula I).
MX2008010801A 2006-02-22 2007-02-21 Indolopiridinas como moduladores de quinesina eg5. MX2008010801A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06110295 2006-02-22
EP06119038 2006-08-16
PCT/EP2007/051688 WO2007096393A1 (en) 2006-02-22 2007-02-21 Indolopyridines as eg5 kinesin modulators

Publications (1)

Publication Number Publication Date
MX2008010801A true MX2008010801A (es) 2008-09-05

Family

ID=37964159

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008010801A MX2008010801A (es) 2006-02-22 2007-02-21 Indolopiridinas como moduladores de quinesina eg5.

Country Status (18)

Country Link
US (1) US8530493B2 (es)
EP (3) EP3862354A1 (es)
JP (1) JP5349056B2 (es)
KR (1) KR101415354B1 (es)
CN (1) CN101389628B (es)
AR (1) AR059609A1 (es)
AU (1) AU2007217560B2 (es)
BR (1) BRPI0708233A2 (es)
CA (1) CA2643488C (es)
EA (1) EA015150B1 (es)
HK (1) HK1205510A1 (es)
IL (1) IL193625A (es)
MX (1) MX2008010801A (es)
NZ (1) NZ571357A (es)
TW (1) TWI377207B (es)
UA (1) UA96592C2 (es)
WO (1) WO2007096393A1 (es)
ZA (1) ZA200808070B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2377847T3 (es) 1999-01-13 2012-04-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
ES2288694T3 (es) 2003-05-20 2008-01-16 Bayer Pharmaceuticals Corporation Diaril ureas para enfermedades mediadas por el receptor del factor de crecimiento derivado de plaquetas.
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
MXPA06012394A (es) 2004-04-30 2007-01-31 Bayer Pharmaceuticals Corp Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
CA2576619A1 (en) 2004-08-18 2006-02-23 Altana Pharma Ag Benzothienopyridines for use as inhibitors of eg5 kinesin
EP2522395A1 (en) 2005-02-03 2012-11-14 TopoTarget UK Limited Combination therapies using HDAC inhibitors
BRPI0610128B1 (pt) 2005-05-13 2021-12-07 Topotarget Uk Limited Composição farmacêutica, e, uso de uma composição
CA2627923C (en) 2005-11-10 2016-01-12 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
EP2033962A1 (en) * 2007-08-22 2009-03-11 4Sc Ag Tetracyclic indolopyridines as EG5 inhibitors
MX2010003230A (es) * 2007-09-25 2010-04-07 Topotarget Uk Ltd Metodos para la sintesis de ciertos compuestos de acido hidroxamico.
EP2098524A1 (en) 2008-03-05 2009-09-09 4Sc Ag Process for preparing enantiomerically pure indolopyrinidines
SI2262493T1 (sl) * 2008-03-07 2015-07-31 Onxeo Dk Branch Of Onxeo S.A. France Postopki zdravljenja z uporabo podaljšane kontinuirane infuzije belinostata
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
CN109467555A (zh) * 2018-06-21 2019-03-15 广东蓝堡生物科技有限公司 一种他达那非衍生物及其制备方法和应用
CN109160914B (zh) * 2018-11-17 2020-06-16 重庆文理学院 一种双吲哚并吡啶类衍生物的合成方法及在抗肿瘤中的应用
CN111529526B (zh) * 2020-04-14 2021-04-23 广州领晟医疗科技有限公司 一种化合物在制备治疗急性胰腺炎的药物中的用途
CN113577063B (zh) * 2021-08-30 2022-08-16 广州领晟医疗科技有限公司 一种化合物在制备治疗炎性肠病的药物中的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0357122A3 (en) 1988-08-29 1991-10-23 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
DE19744257B4 (de) 1997-10-07 2004-04-15 Zentaris Gmbh Beta-Carboline und deren Verwendung zur Behandlung von malignen und anderen, auf pathologischen Zellproliferationen beruhenden Erkrankungen
US6890933B1 (en) * 2000-02-24 2005-05-10 President And Fellows Of Harvard College Kinesin inhibitors
AU2002213421A1 (en) 2000-10-03 2002-04-15 Lilly Icos Llc Condensed pyridoindole derivatives
AU2002310099A1 (en) 2001-05-22 2002-12-03 President And Fellows Of Harvard College Identification of anti-protozoal agents
JP2005510466A (ja) * 2001-09-19 2005-04-21 ファルマシア・コーポレイション 炎症の治療のための置換されたピラゾロ化合物
RU2362775C1 (ru) 2002-02-01 2009-07-27 Астразенека Аб Хиназолиновые соединения
EP1551962A4 (en) 2002-07-08 2007-08-01 Merck & Co Inc MITOTIC KINESIN BINDING CENTER
US7022850B2 (en) * 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
WO2004111193A2 (en) 2003-06-12 2004-12-23 Merck & Co., Inc. Prodrugs of mitotic kinesin inhibitors
US8940896B2 (en) 2004-03-15 2015-01-27 Ptc Therapeutics, Inc. Tetra-cyclic carboline derivatives useful in the inhibition of angiogenesis
CA2576619A1 (en) * 2004-08-18 2006-02-23 Altana Pharma Ag Benzothienopyridines for use as inhibitors of eg5 kinesin
EP1851213A4 (en) 2005-02-10 2010-10-06 Merck Sharp & Dohme INHIBITORS OF MITOTIC KINESINE
EP2035426A1 (en) 2006-06-14 2009-03-18 4Sc Ag Pyrazolopyrimidones
US20100104659A1 (en) 2006-07-13 2010-04-29 Matthias Vennemann Benzopyranopyrazoles

Also Published As

Publication number Publication date
AR059609A1 (es) 2008-04-16
EP3862354A1 (en) 2021-08-11
CA2643488A1 (en) 2007-08-30
EP1996592B1 (en) 2014-08-27
TWI377207B (en) 2012-11-21
US20090233902A1 (en) 2009-09-17
UA96592C2 (uk) 2011-11-25
IL193625A (en) 2015-01-29
TW200815441A (en) 2008-04-01
KR20080098043A (ko) 2008-11-06
BRPI0708233A2 (pt) 2011-05-24
EP2824105B1 (en) 2021-03-31
IL193625A0 (en) 2009-05-04
US8530493B2 (en) 2013-09-10
CA2643488C (en) 2014-08-05
ZA200808070B (en) 2014-03-26
AU2007217560B2 (en) 2012-06-28
KR101415354B1 (ko) 2014-07-04
EA015150B1 (ru) 2011-06-30
EP1996592A1 (en) 2008-12-03
HK1205510A1 (en) 2015-12-18
AU2007217560A1 (en) 2007-08-30
CN101389628B (zh) 2013-02-27
EA200801739A1 (ru) 2009-04-28
WO2007096393A1 (en) 2007-08-30
CN101389628A (zh) 2009-03-18
EP2824105A1 (en) 2015-01-14
JP2009527533A (ja) 2009-07-30
JP5349056B2 (ja) 2013-11-20
NZ571357A (en) 2010-11-26

Similar Documents

Publication Publication Date Title
MX2008010801A (es) Indolopiridinas como moduladores de quinesina eg5.
CY1108399T1 (el) Τετραϋδροπυριδοθειοφαινια
MX2010006143A (es) Azolilmetiloxiranos, su uso y agentes que lo contienen.
MX2009012345A (es) Derivados de 3,3-espiroindolinona.
EA200801852A1 (ru) Индолопиридины в качестве модуляторов кинезина eg5
MX2009004766A (es) Derivados de espiroindolinona.
WO2009074677A3 (en) Pyrazolotriazines
MX2009014247A (es) Compuestos heterociclicos utiles como inhibidores de mk2.
BRPI0717266A2 (pt) Derivados de oxindol
MX2010003918A (es) Compuesto de amida.
SI2024368T1 (sl) Derivati 6,7,8,9-tetrahidro-5h-pirimido(4,5-d)azepin-4-il)-amina kot modulatorji trpv 1 za zdravljenje boleäśine
TW200745027A (en) Novel sulphonylpyrroles
CR7758S (es) Barra de caramelo (paloma)
AU2005273867A1 (en) Benzothienopyridines for use as inhibitors of Eg5 kinesin
NO20081292L (no) Pentasykliske kinaseinhibitorer
TW200740429A (en) Methods and dosage forms for reducing side effects of carbamate compounds
WO2008006883A3 (en) Benzopyranopyrazoles
TW200744567A (en) Phenylethylamine analogs and their use for treating glaucoma
MX2010001303A (es) Compuestos terapeuticos.
MX2010001187A (es) Moduladores del receptor ccr9 y metodos para su uso.
WO2006125815A3 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
WO2006125813A3 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
DE602007006962D1 (en) Thienoä3,2-cüpyridin-7-carbonsäure-derivate
DK2155179T3 (da) Axomadol til smertebehandling arthrose
EA200701626A1 (ru) Новые 6-пиридилфенантридины

Legal Events

Date Code Title Description
FG Grant or registration